NYSE:CVM Stock Quote
Cel-Sci Corporation is a biotechnology company focused on the development of innovative immunotherapy products for the treatment of cancer and other life-threatening diseases
The company is primarily engaged in the research and development of its lead product candidate, which leverages the unique properties of the immune system to combat tumors. With a commitment to enhancing patient outcomes, Cel-Sci explores novel therapeutic approaches and collaborates with research institutions to advance its clinical programs, aiming to bring new hope to patients in need of effective treatment options.
Frequently Asked Questions
How does Cel-Sci engage with investors?
Cel-Sci Corporation engages with investors through regular communication, financial reports, and investor presentations. The company often hosts earnings calls and participates in investor conferences to provide updates on clinical progress, financial health, and strategic initiatives. Transparency and openness are key to fostering trust and interest among investors.
How does Cel-Sci's technology work?
Cel-Sci's technology operates on the premise of stimulating the immune system to recognize and combat cancer. Multikine works by activating specific immune cells, including T-cells and natural killer cells, to target and destroy cancer cells effectively. The goal is to increase the immune response while minimizing toxicity, offering a potentially more effective alternative to traditional therapies.
How has COVID-19 impacted Cel-Sci Corporation?
Like many companies, Cel-Sci Corporation has faced challenges due to the COVID-19 pandemic, including disruptions in clinical trials and supply chains. However, the company has adapted its operations to continue advancing its programs while adhering to safety protocols. Additionally, the pandemic has heightened the focus on immunotherapies, aligning with Cel-Sci's strategic objectives.
What are the financial health indicators for Cel-Sci?
Financial health indicators for Cel-Sci include metrics such as market capitalization, revenue streams, cash reserves, and expenditure on research and development. Investors often examine these indicators, along with clinical trial progress and funding activities, to gauge the company's growth potential and financial stability in the competitive biotechnology landscape.
What are the stages of Cel-Sci's clinical trials?
Cel-Sci's clinical trials occur in several phases: Phase 1 focuses on safety and dosage; Phase 2 assesses efficacy and side effects, and Phase 3 confirms effectiveness and monitors adverse reactions in larger populations. Each phase is rigorously planned to meet regulatory requirements and ensure the safety of participants while advancing potential life-saving therapies.
What clinical results have been reported for Multikine?
Clinical results for Multikine have shown promising efficacy in enhancing survival rates and improving overall outcomes for patients with head and neck cancer. The results from clinical trials indicate that Multikine treatment can lead to a more robust immune response compared to standard therapies alone, although ongoing research is needed to confirm these findings extensively.
What does Cel-Sci Corporation do?
Cel-Sci Corporation is a biotechnology company focused on developing innovative immunotherapy treatments for cancer and other diseases. Their lead product candidate, Multikine, is designed to enhance the immune system's response to cancer. By leveraging the body's natural defense mechanisms, Cel-Sci aims to improve patient outcomes in cancer treatment.
What is Cel-Sci's approach to sustainability?
Cel-Sci Corporation is committed to sustainability and ethical practices in its operations. This includes responsible sourcing of materials, environmentally friendly laboratory practices, and efficient resource usage in clinical trials. The company strives to make a positive impact on public health while minimizing its ecological footprint.
What is Multikine?
Multikine is Cel-Sci's flagship investigational therapy, designed for treating head and neck cancer. It is an immunotherapy that activates the patient's immune system to attack tumors, specifically during the critical time before surgery. Multikine aims to enhance the effectiveness of standard treatments, potentially leading to better survival rates and quality of life for patients.
What is the primary focus of Cel-Sci's research?
Cel-Sci's primary focus is on immunotherapy-based treatments, specifically targeting cancer. The company aims to harness the power of the immune system to recognize and eliminate cancer cells effectively. Their research encompasses various cancer types, with a significant emphasis on head and neck cancers, utilizing their lead product, Multikine.
What is the vision of Cel-Sci Corporation?
The vision of Cel-Sci Corporation is to revolutionize the treatment landscape for cancer by developing advanced immunotherapies. The company aspires to enhance patient survival rates and overall health through innovative therapies that leverage the body’s immune response. Their long-term mission is to contribute significantly to advancements in oncology and related healthcare fields.
What other products is Cel-Sci developing?
In addition to Multikine, Cel-Sci is exploring various other immunotherapy platforms for treating different types of cancer and infectious diseases. They are focused on expanding their product pipeline by researching novel applications of their technology in other therapeutic areas beyond head and neck cancer.
What partnerships does Cel-Sci have?
Cel-Sci Corporation has formed strategic partnerships and collaborations with academic institutions, research organizations, and industry partners to enhance its research and clinical development efforts. These partnerships often facilitate the sharing of resources, knowledge, and expertise, which are crucial for advancing their pipeline of therapies and reaching wider markets.
What regulatory approvals has Cel-Sci received?
Cel-Sci has obtained various regulatory approvals for its clinical trials, allowing them to pursue research in multiple countries. This includes approvals from the U.S. Food and Drug Administration (FDA) for their Phase 3 clinical trials for Multikine. Continually navigating the regulatory landscape is essential for their product development pipeline and eventual market entry.
What should investors know about Cel-Sci's stock?
Investors interested in Cel-Sci’s stock (CVM) should be aware of its volatility, which is common in the biotechnology sector. Notable factors influencing stock performance include clinical trial results, regulatory news, and market conditions. As Cel-Sci continues to advance its clinical programs, understanding these elements is vital for making informed investment decisions.
When did Cel-Sci go public?
Cel-Sci Corporation became publicly traded in 1985. The company's shares are listed on the New York Stock Exchange under the ticker symbol CVM. Since going public, Cel-Sci has raised capital through equity financing to support its research and development efforts and clinical trials for its promising therapies.
Where is Cel-Sci Corporation located?
Cel-Sci Corporation is headquartered in Vienna, Virginia, USA. The company operates in a dynamic biotechnology sector, where it conducts its research, development, and clinical operations. This location allows them to collaborate with various academic and clinical institutions to further their biotechnology initiatives.
Who are the key leaders at Cel-Sci Corporation?
Cel-Sci Corporation's leadership consists of experienced professionals in biotechnology and pharmaceuticals. The company's executives include CEO Geert Kersten and other key management members with extensive backgrounds in drug development, regulatory affairs, and corporate strategy. Their collective expertise drives the company's vision to advance its innovative therapies.
What is the current price of Cel-Sci Corporation Common Stock?
The current price of Cel-Sci Corporation Common Stock is 0.2104
When was Cel-Sci Corporation Common Stock last traded?
The last trade of Cel-Sci Corporation Common Stock was at 4:10 pm EDT on April 2nd, 2025
What is the market capitalization of Cel-Sci Corporation Common Stock?
The market capitalization of Cel-Sci Corporation Common Stock is 16.25M
How many shares of Cel-Sci Corporation Common Stock are outstanding?
Cel-Sci Corporation Common Stock has 77.21M shares outstanding.